Abstract:Medullary thyroid carcinoma (MTC) is a rare neuroendocrine cancer, caused by activating mutations in the RET proto-oncogene, contributing to 13% of all thyroid cancer mortalities. Patients with metastatic MTC treated with RET inhibitors (RETi) can develop resistance through mechanisms currently being investigated. We aim to understand the molecular mechanisms of acquired resistance to RETi and develop novel combination therapies to circumvent resistance to these drugs. We used TT, an MTC cell line, to develop vandetanib-resistant (VanR) lines, at two independent sites, the Medical College of Wisconsin (MCW) and the Pediatric Oncology Branch (POB) at the NCI. We applied a multiomic approach to investigate the mechanisms of resistance, including Spectral karyotyping (SKY) and multiplex interphase Fluorescence in situ Hybridization (miFISH) to study the karyotype, ploidy, and heterogeneity at a single-cell level. Whole exome and RNA-sequencing was done to identify genetic alterations such as acquired mutations, copy number variations, and gene expression changes. In parallel, we performed genome-wide CRISPR gene knockout (KO) in TT cells treated with selpercatinib or vehicle to develop potential synergistic targeted combination therapy with RETi. Additionally, we performed a cytotoxicity screening using the Mechanism Interrogation Plate (MIPE6.0) library containing 2803 investigational drugs, novel agents, and FDA-approved drugs with known mechanisms of action. SKY and miFISH results showed that, for the parental TT_POB cell line, there were 4 copies of chromosome 10 (location of the RET gene), whereas there were 3 copies in TT_POB VanR. This was associated with an increase in the RET variant allele frequency, indicating a loss of heterozygosity of the wildtype allele as a mechanism of resistance, which was confirmed by whole exome sequencing. For TT_MCW VanR, we identified a new RET solvent front (G810S), as well as an increased copy number of RET with an increase in expression. CRISPR KO demonstrated that the knockout of NF1 led to resistance and survival to selpercatinib treatment. The MIPE6.0 screening confirmed resistance to RETi in TT_MCW VanR and sensitivity to multiple MEK inhibitors. In vivo testing in a xenograft mouse model confirmed the synergistic/additive activity of combined selpercatinib with trametinib, a MEK inhibitor. In conclusion, using a multiomic approach, we show that resistance to RETi occurs by an adaptive increase in RET signaling through secondary mutations in RET, and an increase in expression or dose of the mutant RET allele. These genetic events are associated with an activation of RAS signaling, in VanR cell lines, through the ERK/MAPK pathway. Furthermore, we demonstrate that the combination of RET and ERK/MAPK inhibition is synergistic against RET-mutant MTC. Future plans include translating our findings through clinical trials at the NCI. Citation Format: Arwa Fallatah, Abdelrahman Rahmy, Sophia Khan, Hsien-chao Chou, Kerstin Heselmeyer-Haddad, Darawalee Wangsa, David Milewski, Yong Kim, Robert Hawley, Young Song, Xiaohu Zhang, Craig Thomas, Jun S. Wei, Jong-In Park, John Glod, Javed Khan. Combined MEK and RET inhibition overcomes resistance to single agent RET inhibition in medullary thyroid cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1099.

RET Kinase Inhibitors for the Treatment of RET -altered Thyroid Cancers: Current Knowledge and Future Directions

Precision therapy for RET-altered cancers with RET inhibitors

The importance of the RET gene in thyroid cancer and therapeutic implications

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives

Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis

Targeting RET mutation in medullary thyroid cancer

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future

Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions

Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study

Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

Precious Gene: The Application of RET-Altered Inhibitors

Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies

Abstract 1099: Combined MEK and RET inhibition overcomes resistance to single agent RET inhibition in medullary thyroid cancer

Diagnostics, therapeutics and RET inhibitor resistance for RET fusion–positive non-small cell lung cancers and future perspectives

Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs"

Abstract 5835: Genome-Wide CRISPR gene knockout screens combined with selpercatinib identifies potent combination therapies for RET driven medullary thyroid carcinoma

Targeting RET-rearranged non-small-cell lung cancer: future prospects

An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer

Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis